Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

An Open-label, Nonrandomized, Phase IIIb, Single Dose Study to Evaluated the Changes in Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) After Intravitreal Injection of Lucentis® in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)

The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein occlusion (RVO).

Inclusion Criteria:

• Signed written informed consent
• Patients with macular edema due to RVO (confirmed by fundus photography, fluorescein angiography, OCT)
• Male and female aged from 18 to 70
• Baseline best-corrected visual acuity (BCVA) in the study eye was from 20/400 to 20/30 using ETDRS chart

Exclusion Criteria:

• Additional eye disease that could compromise VA
• Ocular inflammation
• Intraocular surgery ≤ 1 month before day 0
• Uncontrolled glaucoma
• Prior treatments with laser photocoagulation or other intervention for macular edema due to BRVO
• Patients aged under 18 or over 71
• Female patient in pregnancy or breast feeding
• Not suitable to regular follow up